Insulin Resistance Intervention After Stroke (IRIS) Trial

The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.

Stanford is now accepting new patients for this trial. Please contact Madelleine Garcia at 6507252326 for more information.



  • drug : placebo
  • drug : pioglitazone

Phase: Phase 3


Ages Eligible For Study:

40 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Madelleine Garcia 6507252326

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: